Collaboration plans for developing biological therapies potentially targeting multiple ophthalmic diseases utilizing APT’s PhageBank™ technology Oyster Point Pharma plans to discuss the potential for bacteriophage in the treatment of ophthalmic diseases at the upcoming Oyster Point Pharma Analyst

Introduction of proprietary ETF™ Gene Therapy and first gene candidate, nerve growth factor (NGF), to target Stages 2 and 3 Neurotrophic Keratopathy (NK) Preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gland injection of an

PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 2021 Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in Q4 2021, if approved by the FDA OLYMPIA Phase 2 Study on Track, with Planned Enrollment of the First Patient in 1H 2021 Continued Organizational Advancement

PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation of data

Conference Call and Webcast Scheduled for May 6, 2021, 4:30 p.m. Eastern Time PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class

George Eliades joins the Board of Directors PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular

Prescription Drug User Fee Act ( PDUFA) target action date is October 17, 2021 U.S. Food and Drug Administration (FDA) has stated that it does not intend to hold an advisory committee meeting to discuss this application Planned U.S. launch of OC-01 (varenicline) nasal spray in fourth quarter of

PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the

OC-01 (Varenicline) Nasal Spray New Drug Application (NDA) Submitted to the U.S. Food and Drug Administration (FDA) for the Treatment of Signs and Symptoms of Dry Eye Disease on December 17, 2020 Phase 2 Clinical Trial Protocol of OC-01 (Varenicline) Nasal Spray in Patients with Neurotrophic

Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET PRINCETON, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class